🏢 What kind of company is Celcuity?

Celcuity (CELC) is a clinical-stage biotech company developing targeted therapies for breast cancer. Headquartered in Minnesota, USA, the company is focused on developing treatments for hormone receptor-positive breast cancer, centered on its lead candidate gedatolisib, and has entered the new drug application stage based on positive Phase 3 clinical results.

The company's core pipeline is gedatolisib, a targeted therapy for hormone receptor-positive, human epidermal growth factor receptor-negative (HR+/HER2-) breast cancer. Gedatolisib demonstrated meaningful improvements in progression-free survival in Phase 3 trials, the company has completed its new drug application, and it is preparing for commercialization as a new drug development company.

💰 How does Celcuity make money?

Business Segment	Revenue Share	Description
New Drug Development	Core	Gedatolisib clinical development
Clinical Pipeline	Key Growth Driver	Breast cancer indication expansion trials
Commercialization Prep	New Expansion	Approval and launch preparation

As a clinical-stage biotech, the company has not yet generated meaningful product revenue, and the structure reflects continued losses driven by R&D investment. The lead candidate gedatolisib has shown standout efficacy data in Phase 3 trials and has entered the new drug application stage, raising commercialization expectations. Additional clinical trials and indication expansion broaden the revenue potential, while regulatory approval, commercialization execution, and funding are the key variables shaping the company's valuation.

📐 Celcuity Market Cap and Company Scale

Market capitalization stands at $4.2B, with an employee headcount of 155명.

As a clinical-stage biotech specialized in developing targeted breast cancer therapies, Celcuity occupies a comparable position to oncology new drug developers such as ARVN (Arvinas), RVMD (Revolution Medicines), and EXEL (Exelixis). Backed by positive clinical data and progress on its new drug application for its lead candidate, the company is gaining commercialization expectations, with clinical and regulatory outcomes serving as the primary drivers of valuation.

📈 Celcuity Outlook and Stock Price Trends

📊 최근 1년 주가흐름

🎯 애널리스트 컨센서스

1.0

매도 보유 적극 매수

목표가 $164 +89.3% 현재 $86

📏 52주 가격 범위

$86

최저 $38 최고 $151

최저 대비 +127.32% 최고 대비 -42.8%

Regulatory approval and successful commercialization of lead candidate gedatolisib, along with indication expansion, are the key drivers of long-term corporate value. Positive Phase 3 data highlights the candidate's potential in the breast cancer treatment market, and additional indications and combination therapies expand the opportunity set. In the near term, however, factors such as uncertainty around approval, commercialization execution risk, ongoing substantial losses and additional funding needs, and competition from rival therapies may drive volatility.

• Gedatolisib approval and commercialization
• Breast cancer indication expansion
• Combination therapy expansion

⚔️ Celcuity Core Strengths and Risks

Positive clinical data and progress in the new drug application for its breast cancer targeted therapy are key strengths, while approval and commercialization uncertainty, persistent losses, and competing therapies are the core risks.

💪 Core Strengths

Positive Clinical Data

The lead candidate demonstrated meaningful efficacy in Phase 3 trials.

Regulatory Progress

The company has completed its new drug application, moving close to commercialization.

Large Indication

Targets a large patient population in hormone receptor-positive breast cancer.

Indication Expansion

Additional indications and combination therapies broaden the market opportunity.

⚠️ Core Risks

Approval Uncertainty

The timing and outcome of new drug approval remain uncertain.

Commercialization Execution

Uncertainty remains around commercialization execution and market penetration post-approval.

Persistent Losses

R&D investment continues to drive losses, and additional funding may be required.

Competing Therapies

The company faces competition from rival therapies in the breast cancer treatment field.

🔄 Celcuity Competitors and Related (Beneficiary) Stocks

Comparable names in the oncology new drug space include targeted oncology developers ARVN (Arvinas), RVMD (Revolution Medicines), and EXEL (Exelixis). Related names such as new drug developers ARWR (Arrowhead Pharmaceuticals) and ALNY (Alnylam Pharmaceuticals) are grouped together within the biotech theme and share the new drug development and commercialization narrative.

⚔️ 경쟁주

종목	회사명	가격	등락	시총	PER	PBR	ROE	배당률
ARVN	Arvinas Inc	$8.03	-3.3%	$518.1M	-	1.3	-42.28%	-
RVMD	Revolution Medicines Inc	$187.53	-2.4%	$39.9B	-	25.0	-76.67%	-
EXEL	Exelixis Inc	$53.03	-5.3%	$13.3B	17.6	7.0	40.99%	-

종목	회사명	가격	등락	시총	PER	PBR	ROE	배당률
ARWR	Arrowhead Pharmaceuticals Inc	$84.65	-3.1%	$11.9B	-	19.4	-46.39%	-
ALNY	Alnylam Pharmaceuticals Inc	$205.52	+0.0%	$27.4B	34.7	20.3	100.7%	-

✅ Celcuity Investor Checklist

Key checkpoints for Celcuity investors are outlined below. Gedatolisib regulatory approval and commercialization progress, additional clinical outcomes, indication expansion, and funding conditions are the key near- and mid-term variables. | Checkpoint | What to Verify | Current Status | |---|---|---| | Regulatory Approval | New drug application and approval progress | Nearing commercialization | | Clinical Results | Additional clinical data | Positive accumulation | | Funding Capacity | Cash burn and additional financing | Needs monitoring | | Commercialization | Launch and market penetration preparation | Under observation | Uncertainty around the timing and outcome of new drug approval is the core risk. There is also uncertainty around commercialization execution and market penetration post-approval, while ongoing substantial losses, additional funding needs, and competition from rival therapies can all act as valuation swing factors.

Celcuity is a clinical-stage biotech nearing commercialization for its lead breast cancer targeted therapy gedatolisib, supported by positive clinical data, with a large target indication and regulatory progress as its key strengths. However, as a new drug development stock with meaningful approval and commercialization uncertainty and sizable losses, a small, diversified position with a long-term perspective is recommended.